Rituximab-Induced Hepatitis C Virus Fulminant Hepatitis (Case Report)

Bitar, Zouheir; Alajmi, Mubarak; Maadarani, Ossama; Bitar, Mohammed Zouheir

doi:10.5171/2014.833705

Cited by 2 publications

(3 citation statements)

References 19 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Textural changes in hair and nails are also observed. A higher incidence of brittle fingernails or toenails, with the formation of vertical nail ridges, were also observed during long-term therapy with ibrutinib [141]. These manifestations appear gradually, with a median reported onset of nine months, and do not represent a dose-limiting toxicity.…”

Section: Dermatologic Complicationsmentioning

confidence: 90%

The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions

Robak¹,

Witkowska²,

Smolewski³

2021

Preprint

View full text Add to dashboard Cite

The use of the Bruton’s tyrosine kinase (BTK) inhibitors has changed the management and clinical history of patients with chronic lymphocytic leukemia (CLL). BTK is a critical molecule that interconnects B-cell antigen receptor (BCR) signaling. BTKIs are classified into two categories: irreversible (covalent) inhibitors and reversible (non-covalent) inhibitors. Ibrutinib is the ﬁrst irreversible BTK inhibitor approved by the U.S. Food and Drug Administration in 2013 as a breakthrough therapy in CLL patients. Subsequently, several studies evaluated the efﬁcacy and safety of new agents with reduced toxicity when compared with ibrutinib. Two other irreversible, second-generation BTK inhibitors, acalabrutinib and zanubrutinib, were developed to reduce ibrutinib-mediated adverse effects. Additionally, new reversible BTK inhibitors are currently under development in an early phase studies to improve their activity and to diminish adverse effects. This review summarizes the pharmacology, clinical efficacy, safety, dosing, drug-drug interactions associated with the treatment of CLL with BTK inhibitors, and examines its further implications.

show abstract

Section: Dermatologic Complicationsmentioning

confidence: 90%

The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions

Robak¹,

Witkowska²,

Smolewski³

2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Severe adverse effects (fulminant hepatitis in HCV liver cirrhosis, serious infections, and sepsis) were rarely noticed when applied for primary glomerulonephritis treatment 26,38,41,42. Respiratory infections were slightly more frequent, as well as cytopenias, when rituximab was applied along with antiviral drugs 32,33,43.…”

Section: Safety Of Rituximab In Cryovasmentioning

confidence: 99%

“… 29 , 31 , 34 – 36 , 40 Severe adverse effects (fulminant hepatitis in HCV liver cirrhosis, serious infections, and sepsis) were rarely noticed when applied for primary glomerulonephritis treatment. 26 , 38 , 41 , 42 Respiratory infections were slightly more frequent, as well as cytopenias, when rituximab was applied along with antiviral drugs. 32 , 33 , 43 In some patients with HCV-related CryoVas, severe systemic reactions after administration of rituximab have been noticed.…”

Section: Safety Of Rituximab In Cryovasmentioning

confidence: 99%

Managing refractory cryoglobulinemic vasculitis: challenges and solutions

Ostojić

Jeremić

2017

JIR

View full text Add to dashboard Cite

Cryoglobulinemia is thought to be a rare condition. It may be an isolated disorder or secondary to a particular disease. According to immunoglobulin composition, cryoglobulinemia is classified into three types. In mixed cryoglobulinemia (types II and III), vascular deposition of cryoglobulin-containing immune complexes and complement may induce a clinical syndrome, characterized by systemic vasculitis and inflammation – cryoglobulinemic vasculitis (CryoVas). Most common clinical manifestations in CryoVas are skin lesions (orthostatic purpura and ulcers), weakness, peripheral neuropathy, Raynaud’s phenomenon, sicca syndrome, membranoproliferative glomerulonephritis, and arthralgia and seldom arthritis. In patients with mixed cryoglobulinemia, prevalence of anti-hepatitis C virus (HCV) antibodies and/or HCV RNA, detected by polymerase chain reaction (PCR), is reported to be up to 90%, indicating a significant role of HCV in the development of this condition. The goals of therapy for mixed cryoglobulinemia include immunoglobulin level reduction and antigen elimination. CryoVas not associated with HCV infection should be treated according to treatment recommendations for small-vessel vasculitides. CryoVas associated with chronic HCV infection should be treated with antivirals along with immunosuppressive drugs, with or without plasmapheresis, depending on disease severity and organ involvement. Patients who do not respond to first-line therapy may achieve remission when treatment with rituximab is started as second-line therapy. In HCV-related CryoVas, antiviral therapy should be given along with rituximab in order to achieve complete or partial remission. Moreover, rituximab has proven to be a glucocorticoid-sparing medication. Other potential therapies for refractory CryoVas include mycophenolate mofetil and belimumab, while tumor necrosis factor (TNF) inhibitors are not effective.

show abstract

Rituximab-Induced Hepatitis C Virus Fulminant Hepatitis (Case Report)

Cited by 2 publications

References 19 publications

The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions

The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions

Managing refractory cryoglobulinemic vasculitis: challenges and solutions

Contact Info

Product

Resources

About